Please assess the completion status of the following clinical trial:

Trial Title: Should Non-eosinophilic Asthmatic Subjects be Treated With Inhaled Corticosteroids?

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Are between 18 and 70 years of age at the time of signing the informed consent.~* Have a diagnosis of asthma according to the Guidelines for the Diagnosis and Management of Asthma and have not been treated with ICS in the previous two months.~* Have a PC20 methacholine less than 8 mg/ml.~* Have a baseline FEV1 greater or equal to 65% of predicted value (at least 6 hours after bronchodilator).~* Are not optimally controlled with short-acting 2 agonists as shown by awakenings due to asthmatic symptoms at least once a week, or regular use of salbutamol on 4 or more occasions per week (excluding exercise prophylaxis) due to asthma symptoms.~* ACQ score equal or greater than 2~* Have sputum eosinophils less than 2%~* Are non smokers or ex-smokers who smoked a maximum of 10 pack/year.~Exclusion Criteria:~* Hospitalized patients within the last 3 months~* Current or recent (within the last month) symptoms of a cold or flu~* Patients with a history of near fatal asthma~* Subjects on inhaled corticosteroids, prednisone, long-acting beta 2 agonists, montelukast or theophylline, within 2 months prior to entry into the study.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 70 Years
- Healthy Volunteers: f

Study Arms:
- Active treatment group (A) (Type: ACTIVE_COMPARATOR): Intervention : treatment with inhaled corticosteroids (Fluticasone) will be administered to this group
- Control group treated with placebo (B) (Type: PLACEBO_COMPARATOR): treatment with placebo

Based on this trial design, predict the completion outcome and termination type (if applicable).